Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-Free Survival in Patients With Adrenocortical Carcinoma at Low-Intermediate Risk of Recurrence

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
18 Jun 2021 This trial has been completed in Germany, according to European Clinical Trials Database.
23 Mar 2021 Results (n=91) of randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in ACC patients at low-intermediate risk of recurrence, presented at the 103rd Annual Meeting of the Endocrine Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com